Single-Tablet Regimens in HIV Therapy

Infectious Diseases and Therapy

Volumn 3, Issue 1, 2014, Pages 1-17

  Astuti, Noemi ^a   Maggiolo, Franco ^a  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

Adherence; Combined antiretroviral therapy; Dolutegravir; Efavirenz; Elvitegravir; Human immunodeficiency virus; Infectious diseases; Quality of life; Rilpivirine; Single tablet regimen

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; COBICISTAT; CREATININE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; RILPIVIRINE; TRIACYLGLYCEROL;

ANXIETY; ANXIETY DISORDER; CONFUSION; COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; GENETIC PREDISPOSITION; HEALTH CARE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; META ANALYSIS (TOPIC); MIXED INFECTION; NAUSEA AND VOMITING; PATIENT ATTITUDE; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SUICIDAL IDEATION; VIRUS REPLICATION;

EID: 84977119451     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-014-0024-z     Document Type: Review

References (79)

1. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354(3): 251-260.
2. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11): 817-33.
3. Blasco AJ, Arribas JR, Boix V, et al. Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012. Enferm Infecc Microbiol Clin. 2012;30(6): 283-93.
4. Antinori A, Marcotullio S, Ammassari A, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2011;34(2): 109-46.
5. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22(15): 1951-60.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, December 1, 2009. http://aidsinfo. nih. gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0. Accessed Dec 2013.
7. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8): 1296-310.
8. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. JAIDS. 2004;36(3): 808-16.
9. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4): 169-77.
10. Ickovics JR, Meade CS. Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences. JAIDS. 2002;31(Suppl 3): S98-102.
11. Tam LW, Chui CK, Brumme CJ, et al. The relationship between resistance and adherence in drug-naïve individuals initiating HAART is specific to individual drug classes. JAIDS. 2008;49(3): 266-71.
12. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24(18): 2835-40.
13. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8(5): 282-92.
14. Aragão F, Vera J, Vaz Pinto I. Cost effectiveness of third agent class in treatment-naïve human immunodeficiency virus-infected patients in Portugal. PLOS one. 2012;7(9): e44774.
15. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3: 371-8.
16. DeJesus E, Ruane P, McDonald C, et al. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixeddose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. HIV Clin Trials. 2008;9(2): 103-14.
17. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40(1): 158-63.
18. Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: selfreport of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. AIDS. 2004;36(3): 808-16.
19. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48(4): 484-8.
20. De Jesus E, Young B, Morales-Ramirez JO, et al. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. JAIDS. 2009;51(2): 163-74.
21. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adher. 2010;4: 115-25.
22. Juday T, Gupta S, Grimm K, Wagner S, Kim E. Factors associated with complete adherence to HIV combination antiretroviral therapy. HIV Clin Trials. 2011;12(2): 71-8.
23. Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilization and costs in a US medicaid population with HIV. BMJ Open. 2013;3: e003028.
24. Vera J, Aragão F, Guimarães M, Vaz Pinto I. Benefit of HAART simplification on adherence, clinical and economic outcomes. In: HIV11, Glasgow UK, November 2012. Abstract P5. http://hivarchive. com/hiv11/uploads/Adherence%20-%20Part%20One. pdf. Accessed Dec 2013.
25. Taneja C, Juday T, Gertzog L, et al. Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens. Expert Opin Pharmacother. 2012;13(15): 2111-8.
26. Cohen C, Davis K, Meyers J. Association of partial adherence to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population. JIAS. 2012;15(suppl. 4): 18060.
27. Antinori A, Angeletti C, Ammassari A, et al. Adherence in HIV-positive patients treated with single-tablet regimens and multi-pill regimens: findings from the COMPACT study. In: HIV11, Glasgow UK, November 2012. Abstract P145. http://www. jiasociety. org/index. php/jias/article/view/18433. Accessed Dec 2013.
28. Laurence J. Treating HIV infection with one pill per day. AIDS Patient Care STDs. 2006;20(9): 601-3.
29. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported non-adherence to antiretroviral therapy in HIV-infected patients. The Swiss HIV Cohort study. JAIDS. 2006;41(3): 385-92.
30. Deschamps AE, De Graeve V, van Wijngaerden E, et al. Prevalence and correlates of non adherence to antiretroviral therapy in a population of HIV patients using medication event monitoring system. AIDS Patient Care STDs. 2004;18(11): 644-57.
31. Heath KV, Singer J, O'Shaughnessy MV, et al. Intentional non adherence due to adverse symptoms associate with antiretroviral therapy. JAIDS. 2002;31(2): 211-7.
32. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. JAIDS. 2002;31: S140-4.
33. Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. JAIDS. 2008;47(3): 384-90.
34. Homar F, Lozano V, Martínez-Gómez J, et al. Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Econ Rev. 2012;2(1): 16 (Epub ahead of print).
35. Juday T, Grimm K, Willig J, Zoe-Powers A, Kim E. A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care. 2011;23(9): 1154-62.
36. Hodder SL, Mounzer K, Dejesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDs. 2010;24(2): 87-96.
37. Palella F, Tebas P, Gazzard B, et al. SPIRIT study: switching boosted PI to rilpivirine in combination with truvada as a single tablet regimen. In: International AIDS conference, Washington DC, July 2012. Abstract TUAB0104. http://www. natap. org/2012/IAS/IAS_05. htm. Accessed Dec 2013.
38. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE. 2012;7(2): e31591.
39. Colombo GL, Di Matteo S, Maggiolo F, et al. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the Single Tablet Regimen (STR). Clinicoecon Outcomes Res. 2013;5: 59-68.
40. German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. JAIDS. 2010;55(3): 323-9.
41. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25(6): F7-12.
42. Elion R, Gathe J, Rashbaum B, et al. The single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; "QUAD") maintains a high rate of virologic suppression, and cobicistat (COBI) is an effective pharmacoenhancer through 48 weeks. In: 50th ICAAC 2010, Boston, USA. Abstract PH-938-B. http://www. hivandhepatitis. com/2010_conference/icaac/posters/Quad. pdf. Accessed Dec 2013.
43. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services; December 2013. http://aidsinfo. nih. gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0. Accessed Jan 2014.
44. European AIDS Clinical Society. Guidelines for the Clinical management and Treatment of HIV Infected Adults in Europe. Version 7. 0, Oct 2013. http://www. eacsociety. org/Guidelines. aspx. Accessed Jan 2014.
45. Antinori A, Marcotullio S, Ammassari A, et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons (November 2013). http://www. salute. gov. it/imgs/C_17_pubblicazioni_1793_allegato. pdf. Accessed Jan 2014.
46. Moyle G, Orkin C, Fisher M, et al. Switching to a single-tablet regimen (STR) of Atripla®(ATR) from a 2 or 3-pill combination of the individual components (efavirenz [EFV], emtricitabine[FTC] and tenofovir df [TDF]) maintains virological suppression: primary endpoint results of a 48-week, open-label study. HIV Med. 2011;12: 79.
47. Deeks ED, Perry CM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs. 2010;70(17): 2315-38.
48. De Jesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomized, double blind, phase 3, non-inferiority trial. Lancet. 2012;379: 2429-38.
49. Rockstroh JK, De Jesus E, Henry K, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. JAIDS. 2013;62(5): 483-6.
50. Charpentier C, Lambert-Niclot S, Visseaux B, et al. Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. JAC. 201;68(10): 2197-8.
51. Ortega-Gonzales E, Garcia Deltoro M, Lopez-AldeguerJ, et al. Trend and prevalence of HIV-1 resistance mutations in the Valencian Autonomous Region (2004-2011) and its relation with the antiretroviral usage pattern: RUVEN study (SEICV-VIH-2012-01). In: 14th EACS, Brussels Belgium, October 2013. Abstract PE9/28. http://www. abstracttosubmit. com/eacs2013/eposter/. Accessed Feb 2014.
52. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine versus efavirenz at 48 weeks in treatment-naïve HIV-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. JAIDS. 2012;60(1): 33-42.
53. Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2013;16 [Epub ahead of print].
54. Eron J, Rockstroh J, Pozniak A, et al. Dolutegravir treatment response by baseline viral load and NRTI backbone in treatment-naïve HIV-infected individuals. In: HIV11, Glasgow UK, November 2012. Abstract P204. http://www. natap. org/2012/interHIV/InterHIV_03. htm. Accessed Dec 2013.
55. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once daily dolutegravir versus twice daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomized, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11): 927-35.
56. Feinberg J, Clotet B, Khuong MA, et al. Once-daily dolutegravir is superior to darunavir/ritonavir in antiretroviral naive adults: 48 week results from Flamingo. In: 53rd ICAAC, Denver USA, September 2013. Abstract H1464a. http://www. natap. org/2013/ICAAC/ICAAC_24. htm. Accessed Dec 2013.
57. Cohen C, Wohl D, Arribas J et al. STaR study: single tablet regimen emtricitabine/rilpivirine/tenofovir is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults. In: HIV11, Glasgow UK, November 2012. Abstract O425. http://www. jiasociety. org/index. php/jias/article/view/18221. Accessed Dec 2013.
58. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013;27(6): 939-50.
59. Nelson M, Winston A, Waters L, et al. Multicentre open-label study of switching from atripla to eviplera for possible efavirenz associated CNS toxicity. In: 53rd ICAAC, Denver USA, September 2013. Abstract H-672-b. http://www. natap. org/2013/ICAAC/ICAAC_47. htm. Accessed Dec 2013.
60. Mills AM, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14(5): 2216-355.
61. Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on integrase inhibitor use in antiretroviral treatment-naïve HIV-infected individuals from HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Department of Health and Human Services; October 30, 2013. http://aidsinfo. nih. gov/contentfiles/upload/adultARV_INSTIRecommendations. pdf. Accessed Jan 2014.
62. Molina JM, Lamarca A, Andrade-Villanueva J, et al. International, randomized, double blinded, 96-week, non-inferiority study of EVG QD versus RAL BID in ARV-experienced patients. Lancet Infect Dis. 2012;12(1): 27-35.
63. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382: 700-8.
64. Sax PE, De Jesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomized, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379: 2439-48.
65. Zolopa A, Sax PE, DeJesus E, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. JAIDS. 2013;63(1): 96-100.
66. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19): 1807-18.
67. Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. JAIDS. 2013;19 [Epub ahead of print].
68. A study to determine safety and efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) in human immunodeficiency virus (HIV)-1 infected antiretroviral therapy (ART) Naïve women (ARIA). http://clinicaltrials. gov/show/NCT01910402?order=0. Accessed Jan 2014.
69. Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs tenofovir disoproxil fumarate, each with elvitegravir, cobicistat and emtricitabine for HIV treatment. In: 20th CROI, Atlanta USA, March 2013. Abstract 99LB. http://www. natap. org/2013/CROI/croi_23. htm. Accessed Dec 2013.
70. Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4): 449-55.
71. King J, Aberg JA. Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS. 2008;22: 1709-17.
72. Schmidt D, Kollan C, Fatkenheuer G et al. Proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany. In: 14th European AIDS conference. Brussels, Belgium, October 2013. PE9/11. http://www. eacs-conference2013. com/fileadmin/templates/eacs/template_FILES/FINAL_EACS13_Final_Program_web. pdf. Accessed Dec 2013.
73. Batmeyer B, Kuecherer C, Houareau C, et al. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 seroconverter cohort. PLoS ONE. 2010;5(10): e12718.
74. Meixenberger K, Scheufele R, Jansen K, et al. In vivo prevalence of transmitted drug-resistant HIV in patients with a known date of HIV-1 seroconversion. In: 14th European AIDS conference. Brussels, Belgium, October 2013. PE9/24. http://www. eacs-conference2013. com/fileadmin/templates/eacs/template_FILES/FINAL_EACS13_Final_Program_web. pdf. Accessed Dec 2013.
75. Chueca N, Camacho-Luque R, Martinez NM, et al. Prevalence of low abundant rilpivirine resistance associated mutations in naïve patients from the south of Spain. In: 14th European AIDS Conference. Brussels, Belgium, October 2013. PE9/16. http://www. eacs-conference2013. com/fileadmin/templates/eacs/template_FILES/FINAL_EACS13_Final_Program_web. pdf. Accessed Dec 2013.
76. Crauwels H, van Heeswijk RP, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013;15(2): 87-101.
77. Sha BM, Schafer JJ, DeSimone JA. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2013;18 [Epub ahead of print].
78. Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013;30: 613-28.
79. NHS England Clinical Reference Group. Clinical Commissioning policy statement: stribild for the treatment of HIV-1 infection in adults. http://www. england. nhs. uk/wp-content/uploads/2013/09/b06-psa1. pdf. Accessed Jan 2014.